Disfunzioni sessuali nei trattamenti con farmaci antipsicotici

Titolo Rivista RIVISTA DI SESSUOLOGIA CLINICA
Autori/Curatori Luigi Lombardo, Roberta Rossi
Anno di pubblicazione 2017 Fascicolo 2017/2
Lingua Italiano Numero pagine 18 P. 5-22 Dimensione file 220 KB
DOI 10.3280/RSC2017-002001
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più clicca qui

Qui sotto puoi vedere in anteprima la prima pagina di questo articolo.

Se questo articolo ti interessa, lo puoi acquistare (e scaricare in formato pdf) seguendo le facili indicazioni per acquistare il download credit. Acquista Download Credits per scaricare questo Articolo in formato PDF

Anteprima articolo

FrancoAngeli è membro della Publishers International Linking Association, Inc (PILA)associazione indipendente e non profit per facilitare (attraverso i servizi tecnologici implementati da CrossRef.org) l’accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche

Nei disturbi psicotici, l’intervento precoce tramite l’impiego di farmaci antipsicotici aumenta la probabilità di un decorso favorevole nel lungo termine. Tuttavia la gestione farmacologica con i farmaci di prima generazione (tipici) è complicata da un’alta percentuale di effetti collaterali, anche sotto forma di disfunzioni sessuali, provocate principalmente dall’aumento delle prolattinemia. I sintomi correlati a quest’ultima comprendono: riduzione del desiderio sessuale, disfunzione erettile, disturbi dell’eiaculazione, irregolarità mestruali, amenorrea, dismenorrea, ginecomastia. Tuttavia, con l’avvento della seconda generazione di farmaci antipsicotici (atipici), i pazienti in trattamento hanno cominciato a mostrare minori effetti negativi sulla sessualità ed una migliore adesione alla terapia. Lo scopo del lavoro è di descrivere gli aspetti epidemiologici e clinici correlati all’impiego di farmaci antipsicotici tipici e atipici e le strategie di intervento farmacologico e psico-sociale per affrontare questo problema.;

Keywords:Disfunzioni sessuali; antipsicotici; schizofrenia; dopamina; prolattina; qualità di vita.

  1. Aizenberg D., Modai I., Landa A., Gil-Ad I., Weizman A. (2001). Comparison of sexual dysfunction in male schizophrenic patients mantained on treatment with classical antipsychotis versus clozapine. The Journal of Clinical Psychiatry, 62(7):541-4.
  2. Anil Kumar M.N., Nagesh B.P., Satheesh R. (2009). A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian Journal of Psychiatry, 51(4):265-71. DOI: 10.4103/0019-5545.5829
  3. Baggaley M. (2008). Sexual dysfunction in schizophrenia: focus on recent evidence. Human Psychopharmacology, 23(3):201-9.
  4. Baytunca M.B., Kose S., Ozbaran B., Erermis S. (2016). Risperidone, quetiapina e Clorpromazina may have induced priapism in an adolescent. Pediatrics Inter-national, 58(1):61-3.
  5. Bo Q., Dong F., Li X., Wang Z., Ma X., Wang C. (2016). Prolactine related symptoms during risperidone manteinance treatment: results from a prospective, multicenter study of schizophrenia. BioMedCentral Psychiatry, 16(1):386.
  6. Brichart N., Delavierre D., Peneau M., Ibrahim H., Mallek A. (2008). Priapism associated with antipsychotic medications: a series of four patients. Progrès en Urologie, 18(10):669-73.
  7. Brom M., Laan E., Everaerd W., Spinhoven P., Trimbos B., Both S. (2016). The effect of a dopamine antagonist on conditioning of sexual arousal in women. Psychopharmacology (Berl), 233(7):1179-89.
  8. Byerly M.J., Lescouflair E., Weber M.T., Bugno R.M., Fisher R., Carmody T., Varghese F., Rush A.J. (2004). An open-label triel of quetiapine for antpsychotic-induced sexual dysfunction. Journal of Sex and Marital Therapy, 30(5):325-32.
  9. Carvalho M.M., Gòis C. (2011). Hyperprolactinemia in mentally ill patients. Acta Médica Portuguesa, 24(6):1005-12.
  10. Chitaia N.N., Danilov D.S., Tiuvina N.A. (2009). Peculiarities of neuroleptic syndrome in women treated with typical and atypical neuroleptics. Zhurnal nevro-logii i psikhiatrii imeni S.S. Korsakova, 109(3):37-43.
  11. Dallon C., Abraham G. (2009). Psychosis and sexuality. Revue Médicale Suisse, 5(195):635-7.
  12. Kelly D.L., Conley R.R. (2004). Sexuality and schizophrenia: a review. Scizophrenia Bulletin, 30(4):767-79.
  13. de Boer M.K., Castelein S., Wiersma D., Schoevers R.A., Knegtering H. (2015). The facts about sexual (dys)function in schizophrenia: an overview of clinically relevant findings. Schizophrenia Bulletin, 41(3):674-86.
  14. Dossenbach M., Dyachkova Y., Pirildar S., Anders M., Khalil A., Araszkiewicz A., Shakhnovich T., Akram A., Pecenak J., McBride M., Treuer T. (2006). Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. European Psychiatry, 21(4):251-8.
  15. Doufik J., Otheman Y., Khalili L., Ghanmi J., Ouanass A. (2014). Antipsychotic-induced priapism and management challenges: a case report. L’Encéphale, 40(6):518-21.
  16. Fortier P., Mottard J.P., Trudel G., Even S. (2003). Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophrenia Bulletin, 29(3):559-72.
  17. Fujii A., Yasui-Furukori N., Sugawara N., Sato Y., Nakagami T., Saito M., Kaneko S. (2010). Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(2):288-93.
  18. Gabay P.M., Fernàndez-Bruno M., Roldàn E. (2006). Sexual behavior in patients with schizophrenia: a review of the literature and survey in patients attending a rehabilitation program. Vertex: Revista Argentina de Psiquiatriá, 17(66):136-44.
  19. Gopalakrishnan R., Jacob K.S., Kuruvilla A., Vasantharaj B., John J.K. (2006). Sildenafil in treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. The American Journal of Psychiatry, 163(3):494-9.
  20. Haefliger T., Bonsack C. (2006). Atypical antipsychotics and sexual dysfunctions: five case-reports associated with risperidone. L’Encephale, 32(1Pt1):97-105.
  21. Hanssens L., L’Italien G., Loze J.Y., Marcus R.N., Pans M., Kerselaers W. (2008). The effect of antipsychotic madication on sexual function and serum prolactine levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BioMedCentral Psychiatry, 8:95. DOI: 10.1186/1471-244X-8-9
  22. Higgins A., Barker P., Begley C.M. (2005). Neuroleptic medication and sexuality: the forgotten aspect of education and care. Journal of Psychiatric and Mental Health Nursing, 12(4):439-46.
  23. Huguelet P., Mohr S., Boucherie M., Yaron M., Perroud N., Bianchi-Demicheli F. (2015). An exploration of sexual desire and sexual activities of women with psychosis. Revue Médicale Suisse, 11(486):1691-5.
  24. Iagubov M.I., Shtark L.N. (2011). Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disor-ders. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova, 111(9Pt2):57-60.
  25. Inder W.J., Castle D. (2011). Antipsychotic-induced hyperprolactinaemia. The Australian and New Zealand Journal of Psychiatry, 45(10):830-7. DOI: 10.3109/00048674.2011.58904
  26. Jeong H.G., Lee M.S., Lee H.Y., Ko Y.H., Han C., Joe S.H. (2012). Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. International Clinical Psychopharmacology, 27(4):177-83.
  27. Kasperek-Zimowska B., Brodniak W.A., Sarol-Kulka A. (2008). Sexual disorders in schizophrenia-overview of research literayure. Psychiatria Polska, 42(1):97-104.
  28. Kelly D.L., Conley R.R. (2006). A randomidez double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology, 31(3):340-6.
  29. Kheng Yee O., Muhd Ramil E.R., Che Ismail H. (2014). Remitted male schizophrenia patients with sexual dysfunction. The Journal of Sexual Medicine, 11(4):956-65.
  30. Kirshner A., Davis R.R. (2006). Priapism associated with the switch from oral to injectable risperidone. Journal of Clinical Psychopharmacology, 26(6):626-8.
  31. Kleitz-Nelson H.K., Cornil C.A., Balthazart J., Ball G.F. (2010). Differential effects of central injections of D1 and D2 receptor agonists and antagonists on male sexual behavior in Japanese quail. The European Journal of Neuroscience, 321119-129.
  32. Knegtering H., van den Bosch R., Castelein S., Bruggeman R., Sytema S., van Os J. (2008). Are sexual side effects of prolactin-rasing antipsychotics reducible to serum prolactin? Psychoneuroandocrinology, 33:711-17.
  33. Konarzewska B., Wolczyński S., Szulc A., Galińska B., Poplawska R., Waszkiewicz N. (2009). Effect of risperidone and olanzapine on reproductive hormones, psychopatology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology, 34(1):129-39.
  34. Loh C., Leckband S.G., Meyer JM.., Turner E. (2004). Risperidone-induced retro-grade ejaculation: case report and review of the literature. International Clinical Psychopharmacology, 19(2):111-2. DOI: 10.1097/00004850-200403000-0000
  35. McCann E. (2003). Exploring sexual and relationship possibilities for people with psychosis--a review of the literature. Journal of Psychiatric and Mental Health Nursing, 10(6):640-9.
  36. Menon A., Williams R.H., Watson S. (2006). Increased libido associated with quetiapine. Journal of Psychopharmacology, 20(1):125-7. DOI: 10.1177/026988110605973
  37. Macdonald S., Halliday J., Mac Ewan T., Sharkey V., Farrington S., Wall S., Mc Creadie R.G. (2003). Nithsdale Schizophrenia Survey 24: sexual dysfunction. The British Journal of Psychiatry: The Journal of Mental Science, 18250-56.
  38. Mesa N., de la Oliva J., Bagney A., Jimenez-Arriero M.A., Rodriguez-Jimenez R. (2013). Dopamine partial agonism in antipsychotic-induced sexual dysfunction. Actas Españolas de Psiquiatría. 41(2):130-2.
  39. Montalvo I., Ortega L., Lòpez X., Solè M., Monseny R., Franch J., Vilella E., labad J. (2013). Changes in prolactin levels and sexual function in young psychotic patients after switching fron long-acting injectable risperidone to paliperidone palmitate. International Clinical Psychopharmacology, 28(1):46-9.
  40. Montejo A.L., Majadas S., Roco-Villademoros F., Liorca G., De La Gàndara J., Franco M., Martin-Carrasco M., Aguera L., Prieto N.; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. (2010). Frequancy of sexual dysfunction in patients with a psychotic disorder receiving antipsy-chotics. The Journal of Sexual Medicine, 7(10):3404-13.
  41. Montejo A.L., Montejo L., Navarro-Cremades F. (2015). Sexual side-effects of antidepressant and antipsychotic drugs. Current Opinion in Psychiatry. 28(6):418-23. DOI: 10.1097/YCO.000000000000019
  42. Muench J., Hamer A.M. (2010). Adverse effects of antipsychotic medications. American Family Physician/GP, 81(5):617-22.
  43. Nebhinani N., Grover S., Avasthi A. (2012). Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire. The Primary Care Companion for CNS Disorders [electronic resource], 14(2). pii: PCC.11m01199.
  44. Park Y.W., Kim Y., Lee J.H. (2012). Antipsychotic-induced sexual dysfunction and its management. The World Journal of Men’s Health, 30(3):153-9.
  45. Quinn C., Browne G. (2009). Sexuality of people living with a mental illness: a collaborative challenge for mental health nurses. International Journal of Mental Health Nursing, 18(3):195-203.
  46. Quinn C., Happell B., Browne G. (2012). Opportunity lost? Psychiatric madications and problems with sexual function: a role for nurses in mental health. Journal of Clinical Nursing, 21(3-4):415-23.
  47. Raghuthaman G., Venkateswaran R., Krishnadas R. (2015). Adjuntive aripiprazole in risperidone-induced hyperprolactinemia: double-blind, randomised, placebo-controlled trial. British Journal of Psychiatry Open, 1(2):172-7. eCollection 2015.
  48. Rosenberg KP., Bleiberg K.L., Koscis J., Gross C. (2003). A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. Journal of Sex and Marital Therapy, 29(4):289-96. DOI: 10.1080/0092623039019552
  49. Sathish Kumar S.V., Sinha V.K. (2015). Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Indian Journal of Psychiatry, 57(4):386-91. DOI: 10.4103/0019-5545.17185
  50. Schmidt H.M., Hagen M., Kriston L., Soares-Weiser K., Maayan N., Berner M.M. (2012). Management of sexual dysfunction due to antipsychotic drug therapy. The Cochrane Database of Systematic Reviews [electronic resource], 14; 11:CD003546.
  51. Schöttle D., Kammerahl D., Huber J., Briken P., Lambert M., Huber C.G. (2009). Sexual problems in patients with schizophrenia. Psychiatrische Praxis, 36(4):160-8.
  52. Serretti A., Chiesa A. (2011a). Sexual side effects of pharmacological treatment of psychiatric diseases. Clinical Pharmacology and Therapeutics, 89(1):142-7.
  53. Serretti A., Chiesa A. (2011b). A meta-analysis of sexual dysfunctionin psychiatric patients taking antipsychotics. International Clinical Psychopharmacology, 26: 130-40.
  54. Shah S.K. (2013). A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu University Medical Journal, 11(42):121-5. DOI: 10.4103/0019-5545.5829
  55. Skodlar B., Nagy M.Z. (2009). Sexuality and psychosis. Psychiatria Danubina, 21 suppl.. 1:111-6.
  56. Sood S., James W., Ballon M.J. (2008). Priapism associated with atypical antipsychotic medications: a review. International Clinical Psychopharmacology, 23(1):9-17.
  57. Tardieu S., Micallef J., Bonierbale M., Frauger E., Lançon C., Blin O. (2006). Sexual behaviour in schizophrenic patients: the impact of antipsychotics. L’Encephale, 32(5Pt1):697-704.
  58. Van Bruggen M., van Amelsvoort T., Wouters L., Dingemans P., da Haan L., Linszen D. (2009). Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroandocrinology, 34(7):989-95.
  59. Voermans J.M., Van H.L., Peen J., Hengeveld M.W. (2012). Is there adequate discussion between psychiatrists and their patients’ sexual problems?. Tijdschrift Voor Psychiatrie, 54(1):9-16.
  60. Wirshing D.A., Pierre J.M., Marder S.R., Saunders C.S., Wirshing W.C. (2002). Sexual side effects of novel antipsychotic medications. Schizophrenia Re-search, 56(1-2):25-30. DOI: 10.1016/S0920-9964(01)00271-
  61. Yektaș Ç., Tufan A.E. (2016). Spontaneous Ejaculations in an adolescent with olanzapine use: case report. Clinical Neuropharmacology, 39(3):157-8. DOI: 10.1097/WNF.000000000000014

Luigi Lombardo, Roberta Rossi, Disfunzioni sessuali nei trattamenti con farmaci antipsicotici in "RIVISTA DI SESSUOLOGIA CLINICA" 2/2017, pp 5-22, DOI: 10.3280/RSC2017-002001